Clinical Trial

The PENTO Protocol in Medication-related Osteonecrosis of the Jaw

Study acronym: PENTO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Medication-related osteonecrosis of the jaw (MRONJ) occurs after taking bisphosphonates or targeted therapies. It leads to a significant decrease in quality of life with pain, eating and chewing disorders, and malnutrition. Current treatments are only partially effective. PENTO (pentoxifylline and tocopherol) has been shown to be effective in maxillary osteoradionecrosis. The objective of this study is to evaluate the proportion of bone recovery in patients receiving PENTO in MRONJ at 12 months.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-03-20; most recent amendment 2026-06-23.
Status change: Not Yet Recruiting → Recruiting 2024-03-11
Trial Details
NCT Number NCT05795647
Lead Sponsor University Hospital, Limoges
Conditions Medication-related Osteonecrosis of the Jaw (MRONJ)
Enrollment 17 participants
Start Date 2024-02-29
Primary Completion 2027-04-07 (estimated)
Study Completion 2028-04-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-24